$313 Million is the total value of Tri Locum Partners LP's 61 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UA | Exit | UNDER ARMOUR INCcl c | $0 | – | -11,603 | -100.0% | -0.03% | – |
| VTRS | Exit | VIATRIS INC | $0 | – | -10,379 | -100.0% | -0.04% | – |
| NRZ | Exit | RITHM CAPITAL CORP | $0 | – | -13,531 | -100.0% | -0.05% | – |
| KMI | Exit | KINDER MORGAN INC DEL | $0 | – | -10,324 | -100.0% | -0.07% | – |
| BRKB | Exit | BERKSHIRE HATHAWAY INC DELcl b new | $0 | – | -588 | -100.0% | -0.08% | – |
| CTAS | Exit | CINTAS CORP | $0 | – | -414 | -100.0% | -0.08% | – |
| CL | Exit | COLGATE PALMOLIVE CO | $0 | – | -2,701 | -100.0% | -0.08% | – |
| PRU | Exit | PRUDENTIAL FINL INC | $0 | – | -2,463 | -100.0% | -0.08% | – |
| DOV | Exit | DOVER CORP | $0 | – | -1,512 | -100.0% | -0.08% | – |
| FGEN | Exit | FIBROGEN INCput | $0 | – | -122,500 | -100.0% | -0.12% | – |
| INBX | Exit | INHIBRX INC | $0 | – | -15,268 | -100.0% | -0.15% | – |
| ALDX | Exit | ALDEYRA THERAPEUTICS INC | $0 | – | -73,067 | -100.0% | -0.23% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -70,588 | -100.0% | -0.29% | – |
| COGT | Exit | COGENT BIOSCIENCES INC | $0 | – | -66,885 | -100.0% | -0.29% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -24,201 | -100.0% | -0.32% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -33,750 | -100.0% | -0.35% | – |
| CERE | Exit | CEREVEL THERAPEUTICS HLDNG I | $0 | – | -41,292 | -100.0% | -0.49% | – |
| MRSN | Exit | MERSANA THERAPEUTICS INC | $0 | – | -428,307 | -100.0% | -0.52% | – |
| Exit | VENTYX BIOSCIENCES INC | $0 | – | -57,800 | -100.0% | -0.70% | – | |
| Exit | ROIVANT SCIENCES LTD | $0 | – | -202,406 | -100.0% | -0.76% | – | |
| MRUS | Exit | MERUS N V | $0 | – | -101,691 | -100.0% | -1.00% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -29,506 | -100.0% | -2.08% | – |
| Exit | STEVANATO GROUP S P A | $0 | – | -176,359 | -100.0% | -2.12% | – | |
| NARI | Exit | INARI MED INC | $0 | – | -113,441 | -100.0% | -2.45% | – |
| ILMN | Exit | ILLUMINA INC | $0 | – | -40,832 | -100.0% | -2.84% | – |
| LEGN | Exit | LEGEND BIOTECH CORPsponsored ads | $0 | – | -116,768 | -100.0% | -3.00% | – |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -24,597 | -100.0% | -3.22% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -96,274 | -100.0% | -3.65% | – |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -160,660 | -100.0% | -5.26% | – |
| JNJ | Exit | JOHNSON & JOHNSON | $0 | – | -127,362 | -100.0% | -7.84% | – |
| LLY | Exit | LILLY ELI & COunit | $0 | – | -54,369 | -100.0% | -9.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| FEMASYS INC | 10 | Q3 2023 | 0.5% |
| REGENERON PHARMACEUTICALS | 9 | Q3 2023 | 13.8% |
| LILLY ELI & CO | 9 | Q2 2023 | 9.5% |
| X4 PHARMACEUTICALS INC | 8 | Q3 2023 | 3.0% |
| XENON PHARMACEUTICALS INC | 8 | Q3 2023 | 2.4% |
| ARGENX SE | 7 | Q3 2023 | 12.8% |
| STEVANATO GROUP S P A | 7 | Q2 2023 | 5.8% |
| PROTAGONIST THERAPEUTICS INC | 7 | Q2 2023 | 7.1% |
| AVADEL PHARMACEUTICALS PLC | 7 | Q3 2023 | 6.4% |
| BELLUS HEALTH INC NEW | 7 | Q3 2022 | 4.3% |
View Tri Locum Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-27 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View Tri Locum Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.